Please Wait
Applying Filters...
menu
    • menu
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Atezolizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Design Therapeutics Reports Friedreich's Ataxia Data Readout
    Design Therapeutics Reports Friedreich's Ataxia Data Readout

    19 May 2026

    // ENDPOINTS

    https://endpoints.news/design-therapeutics-friedreich-ataxia-data-vincentages-obesity-results-from-china/

    ENDPOINTS
    19 May 2026
    Share Share
    FDA Approves Tecentriq for ctDNA-Guided Adjuvant Bladder Cancer
    FDA Approves Tecentriq for ctDNA-Guided Adjuvant Bladder Cancer

    15 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-15/fda-approves-genentech-s-tecentriq-for-adjuvant-muscle-invasive-bladder-cancer-with-ctdna-guided-tre

    PHARMIWEB
    15 May 2026
    Share Share
    Adagene Showcases Muzastotug's Role at AACR 2026
    Adagene Showcases Muzastotug's Role at AACR 2026

    17 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7184487

    FIRSTWORD PHARMA
    17 Apr 2026
    Share Share
    ORYZON Initiates Phase Ib Study Of Iadademstat In Extensive
    ORYZON Initiates Phase Ib Study Of Iadademstat In Extensive

    09 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/09/3234486/0/en/ORYZON-Announces-First-Patient-Dosed-in-an-Investigator-Initiated-Phase-Ib-Study-of-Iadademstat-in-Extensive-Stage-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    09 Feb 2026
    Share Share
    FDA Accepts Exelixis' NDA for Zanzalintinib + ICI in Cancer
    FDA Accepts Exelixis' NDA for Zanzalintinib + ICI in Cancer

    02 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260130221586/en/Exelixis-Announces-U.S.-FDA-Accepted-the-New-Drug-Application-for-Zanzalintinib-in-Combination-with-an-Immune-Checkpoint-Inhibitor-for-Patients-with-Metastatic-Colorectal-Cancer

    BUSINESSWIRE
    02 Feb 2026
    Share Share
    Natera Submits Signatera CDx PMA to FDA
    Natera Submits Signatera CDx PMA to FDA

    02 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260129560151/en/Natera-Submits-Signatera-CDx-PMA-to-FDA

    BUSINESSWIRE
    02 Feb 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.